• Login
    • Join
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Exclusives
    • Manufacturing
    • Markets
    • Top 10 Orthopedic Device Firms
    • Buyers' Guide
    • Events
    • More
  • Magazine
  • News
  • Exclusives
  • Manufacturing
  • Markets
  • Top 10 Orthopedic Device Firms
  • Buyers' Guide
  • Events
  • Current & Past Issues
    Features
    Departments
    Columns
    Editorial
    Digital Edition
    Subscribe Now
    Advertise Now
    Editorial Guidelines
    eNewsletter Archive
    Top Features
    From Nitinol to Nanotubes: A Materials Science Roundtable

    In Good Repair: Trauma Technologies Under Review

    Anxious Undertones: A Review of 2019

    Automated Analysis Advantages for Part Validation

    Tried and True Metalworking
    Breaking News
    Certifications
    Clinical Trials
    Device Approvals & Patents
    Financial & Deals
    International
    Market Data & Trends
    OEM News
    People
    Product & Service Releases
    Products
    Quality, Recalls & Risk
    Regulatory & Legal
    Supplier & Contract Mfg.
    Live From Shows
    Top News & Features
    FDA OKs First Test to Help Screen for Newborn Duchenne Muscular Dystrophy

    Europe, North America Comprise More Than 80 Percent of Global Bone Marrow Transplantation Demand

    TriMed Closes Out FDA Warning Letter

    FDA OKs Shoulder Innovations' Augmented Glenoids for Total Shoulder System

    OrthoGrid Systems Receives FDA 510(k) Clearance for New PhantomMSK Trauma Application
    3-D Printing/Additive Mfg.
    Assembly & Automation
    Biocompatibility & Testing
    Clean Room
    Coatings/Surface Modification
    Contract Manufacturing
    Design
    Extrusion
    Finishing
    Forging & Casting
    Instruments, Cases & Trays
    International/Offshoring
    Laser Processing
    Materials
    Machining & Tooling
    Molding
    Packaging & Sterilization
    Prototyping
    Research & Developement
    Software & Quality
    Staffing, Training & Prof. Dev.
    Supply Chain

    FDA OKs First Test to Help Screen for Newborn Duchenne Muscular Dystrophy

    TriMed Closes Out FDA Warning Letter

    Sounding Board: Looking Back at 2019 and Gazing at 2020

    OrthoGrid Systems Receives FDA 510(k) Clearance for New PhantomMSK Trauma Application

    Clinical Study of Cell Therapy for Disc Degeneration Clears Final Planned Safety Review
    Biologics
    Bracing/Prosthetics
    Extremities
    Imaging
    Instruments
    Large Joint
    MIS/Robotics
    Spine/Neurology
    Trauma/Sports
    Top Markets
    Sounding Board: Looking Back at 2019 and Gazing at 2020

    Molybdenum-Rhenium Biomaterial: Something ‘MoRe’?

    New Exoskeleton Shoulders Rehab Burden for Stroke Patients

    Repairing Knee Cartilage Defects with the Patient's Own Cells

    Compamed 2019 Preview Report
    Companies
    Categories
    Company Capabilities
    White Papers
    Add New Company
    International Buyers Guide Companies
    Huron Tool & Cutter Grinding Co. Inc.

    Oberg Medical

    Tegra Medical

    Nelson Laboratories LLC

    Tecomet
    Industry Events
    Webinars
    • Magazine
      • Current & Past Issues
      • Features
      • Editorial
      • Departments
      • Columns
      • Digital Edition
      • eNewsletter Archive
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
    • Breaking News
    • Buyers' Guide
      • Companies
      • Categories
      • Company Capabilities
      • White Papers
      • Add Your Company
    • Manufacturing
      • 3-D Printing/Additive Mfg.
      • Assembly & Automation
      • Biocompatibility & Testing
      • Clean Room
      • Coatings/Surface Modification
      • Contract Manufacturing
      • Design
      • Extrusion
      • Finishing
      • Forging & Casting
      • Instruments, Cases & Trays
      • International/Offshoring
      • Laser Processing
      • Materials
      • Machining & Tooling
      • Molding
      • Packaging & Sterilization
      • Prototyping
      • Research & Developement
      • Software & Quality
      • Staffing, Training & Prof. Dev.
      • Supply Chain
    • Markets
      • Biologics
      • Bracing/Prosthetics
      • Extremities
      • Imaging
      • Instruments
      • Large Joint
      • MIS/Robotics
      • Spine/Neurology
      • Trauma/Sports
    • Top 10 Orthopedic Device Firms
    • Online Exclusives
    • Slideshows
    • Videos
    • Webinars
    • Events
      • Industry Events
    • Live from Show Event
    • About Us
      • About Us
      • Contact Us
      • Privacy Policy
      • Terms of Use
      • Advertise With Us
    Breaking News

    RTI Surgical's Sales Down 3 Percent Last Year

    Company reported fourth-quarter 2016 revenue loss of 6 percent.

    RTI Surgical
    Related CONTENT
    • RTI Surgical Names Interim CEO
    • Medicare Bundled-Payments Model Cut Joint Replacement Costs by Over 20 Percent
    • SpineGuard's 2016 Revenue Jumps 18 Percent
    • Medicrea's Annual Sales Grow 6 Percent in 2016
    • RTI Surgical Names CEO
    Business Wire03.09.17
    It's time for a reset at RTI Surgical Inc.

    As it prepares to welcome its new CEO Camille Farhat, the company released disappointing fourth-quarter and full-year 2016 financial results. Although RTI delivered a strong performance in its direct business, with double-digit growth reported in its spine, surgical specialties, cardiothoracic and international divisions, its commercial/other business declined during 2016, primarily due to extraordinarily high commercial orders in 2015. However, the company's finances did show signs of stabilization during the year.

    “We are focused on execution and, in parallel with the pending arrival of Camille, we are executing an initial restructuring plan to reduce operating costs and streamline and improve our platform for growth," RTI Interim CEO Robert Jordheim said. "As a result of this initial cost rationalization, we expect to incur a pre-tax charge of approximately $4 million for severance-related expenses, a majority of which will be recorded in the first quarter of 2017. This initial plan is expected to save the company approximately $8 million of annualized expenses beginning in the first quarter of 2017 and is a first step toward optimizing our expense structure to establish an efficient and more flexible platform upon which to grow profitably.”

    Fourth Quarter 2016
    RTI reported a net loss of $12 million in 2016’s fourth quarter, or 21 cents per fully diluted common share, mainly due to pre-tax charges totaling $16 million related to excess hernia and sports medicine inventory and asset impairment of the company’s German subsidiary. Excluding these charges, adjusted net income per fully diluted common share was 1 cents and adjusted earnings before interest, taxes, depreciation and amortization (adjusted EBITDA) was $6.1 million for the fourth quarter of 2016 (ended Dec. 31).
     
    Worldwide revenues were $71.3 million for the fourth quarter of 2016, a decrease of 6 percent, domestic revenues were $64.6 million, a decrease of 9 percent, and international revenues were $6.8 million, an increase of 24 percent from 2015’s fourth quarter. The decrease in domestic revenue was primarily due to lower orders in the commercial/other business in 2016 coming off a very strong 2015; partially offset by strong growth in the domestic direct businesses. The increase in international revenues was mainly driven by growth in Asia, primarily in Spine.

    Direct revenues were $44.5 million for the fourth quarter of 2016, an increase of 22 percent compared to the fourth quarter of 2015, with particular strength in Spine. RTI’s spine business continues to be one of the fastest-growing spine businesses in the United States, primarily due to increases in surgeon users and distributor relationships. Commercial/other revenues were $26.8 million for the fourth quarter of 2016. Spinal sales surged 37 percent in the fourth quarter to $21.4 million. Sports medicine and orthopedic product revenue climbed 1 percent to $13.2 million.
     
    The company has begun implementing restructuring actions targeted at rightsizing investments toward those businesses and market areas with the greatest potential for long-term growth. This effort is ongoing and is expected to result in both cost savings and additional revenue opportunities over the near- and long-term.
     
    Full Year 2016
    Worldwide revenues were $272.9 million for the full year 2016, a decrease of 3 percent compared to revenues for the full year 2015, mainly due to the same factors impacting fourth quarter 2016 worldwide revenues. Domestic revenues were $247.8 million for the full year 2016, a decrease of 5 percent compared to domestic revenues for the full year 2015. International revenues were $25.1 million for the full year 2016, an increase of 15 percent compared to international revenues for the full year 2015. On a constant currency basis, international revenues for the full year 2016 increased 15 percent compared to international revenue for the full year 2015.
     
    Direct revenues were $160.8 million for the full year 2016, an increase of 16 percent compared to direct revenues for the full year 2015. The company experienced double digit growth in the spine, surgical specialties, cardiothoracic, and international businesses. Commercial/other revenues were $112 million for the full year 2016, a decrease of 22 percent compared to commercial/other revenues for the full year 2015. The decline in commercial/other business is primarily related to significantly high orders in 2015 with lower orders in 2016, however the commercial business showed signs of stabilization during the year. In addition, RTI is taking actions to reinvigorate this business by strengthening relationships and investing in innovation.

    The company's spinal proceeds jumped 27.4 percent last year to $73.9 million; conversely, sports medicine and orthopedic product sales fell 1.1 percent to $50.1 million.
     
    During the year, the company recorded pre-tax charges totaling $25.6 million as follows: $9.6 million related to hernia and sports medicine inventory, $5.6 million related to asset impairment of the company’s German subsidiary, $1.2 million related to strategic review costs, $4.4 million related to CEO transition and retirement costs, $2.7 million related to contested proxy costs, $1.1 million related to restructuring, and $1 million related to severance. In addition, the company also recorded a foreign net operating loss valuation reserve of $1.2 million.
     
    Net loss applicable to common shares was $18.1 million for the full year 2016, compared to net income applicable to common shares of $11.6 million for the full year 2015. Net loss per common share was 31 cents for the full year 2016, based on 58.2 million common shares outstanding, compared to net income per fully diluted common share of 20 cents for the full year 2015, based on 58.6 million fully diluted common shares outstanding.
     
    Adjusted net income applicable to common shares was $2.1 million for the full year 2016, compared to adjusted net income applicable to common shares of $13.4 million for the full year 2015.

    Adjusted net income per fully diluted common share was 4 cents for the full year 2016, based on 58.5 million fully diluted common shares outstanding, compared to adjusted net income per fully diluted common share of 23 cents for the full year 2015, based on 58.6 million fully diluted common shares outstanding.
     
    Adjusted EBITDA was $29.8 million for the full year 2016 (11 percent of 2016 revenues) compared to $46.3 million for the full year 2015 (16 percent of 2015 revenues).
     
    Fiscal 2017 Outlook
    RTI will remain focused in 2017 on execution, continued innovation and profitable growth across each of its business lines and geographies. The company has developed its guidance based on a conservative view of its current restructuring and operational improvement program, its current business profile and existing market conditions.
     
    Within this context, RTI expects full year revenues for 2017 to be between $274 million and $285 million. Compared to the full year 2016, direct revenue is expected to grow mid-to-high single digits on a percentage basis, while commercial/other revenue is expected to account for a relatively flat to low single-digit decline on a percentage basis.
     
    Excluding the approximately $4 million pre-tax charge for severance-related expenses in 2017, adjusted full year net income per fully diluted common share is expected to be in the range of 5 cents to 10 cents, based on 59.5 million fully diluted common shares outstanding.
    Related Searches
    • orthopedic
    • surgeon
    • streamline
    • innovation
    Suggested For You
    RTI Surgical Partners with Advanced Regenerative Manufacturing Institute RTI Surgical Partners with Advanced Regenerative Manufacturing Institute
    What’s New in Orthopedics in the ED? What’s New in Orthopedics in the ED?
    K2M Reports 9.9 Rise in First Quarter Revenue K2M Reports 9.9 Rise in First Quarter Revenue
    RTI Surgical Reports 4 Percent Rise in First-Quarter Revenue RTI Surgical Reports 4 Percent Rise in First-Quarter Revenue
    Zimmer Biomet Zimmer Biomet's First-Quarter Sales Rise 3.8 Percent
    Exactech Exactech's First-Quarter Revenue Rises 6 Percent
    Vexim First-Quarter Revenue Rises 19 Percent Vexim First-Quarter Revenue Rises 19 Percent
    MedTech Industry Lost Nearly 29,000 Jobs While Device Tax In Effect MedTech Industry Lost Nearly 29,000 Jobs While Device Tax In Effect
    RTI Surgical Names CEO RTI Surgical Names CEO
     Medicrea Medicrea's Annual Sales Grow 6 Percent in 2016
    SpineGuard SpineGuard's 2016 Revenue Jumps 18 Percent
    Medicare Bundled-Payments Model Cut Joint Replacement Costs by Over 20 Percent Medicare Bundled-Payments Model Cut Joint Replacement Costs by Over 20 Percent
    RTI Surgical Names Interim CEO RTI Surgical Names Interim CEO

    Related Breaking News

    • FDA OKs First Test to Help Screen for Newborn Duchenne Muscular Dystrophy

      FDA OKs First Test to Help Screen for Newborn Duchenne Muscular Dystrophy

      PerkinElmer's test measures dried blood samples collected from the prick of a newborn’s heel 24 to 48 hours after birth.
      U.S. Food and Drug Administration 12.13.19

    • Biologics
      Europe, North America Comprise More Than 80 Percent of Global Bone Marrow Transplantation Demand

      Europe, North America Comprise More Than 80 Percent of Global Bone Marrow Transplantation Demand

      The increasing prevalence of myeloma is leading to a rise in the execution of bone marrow transplantation procedures, study concludes.
      Persistence Market Research 12.12.19

    • Extremities
      TriMed Closes Out FDA Warning Letter

      TriMed Closes Out FDA Warning Letter

      Receipt of closeout letter signals the completion of a 24-month initiative to expand and enhance quality management systems.
      Business Wire 12.11.19


    • Extremities
      FDA OKs Shoulder Innovations

      FDA OKs Shoulder Innovations' Augmented Glenoids for Total Shoulder System

      The new InSet Plus glenoids feature an angled articular surface.
      PR Newswire 12.10.19

    • Trauma/Sports
      OrthoGrid Systems Receives FDA 510(k) Clearance for New PhantomMSK Trauma Application

      OrthoGrid Systems Receives FDA 510(k) Clearance for New PhantomMSK Trauma Application

      Trauma application added to universal PhantomMSK platform; one platform with use across a variety of procedures.
      OrthoGrid 12.10.19

    • Tyber Medical Opens $8M Office and Manufacturing Facility

      Tyber Medical Opens $8M Office and Manufacturing Facility

      Creates about 30 additional jobs for Lehigh Valley's second-fastest growing company.
      PR Newswire 12.10.19


    • Extremities | Software & Quality
      FDA OKs Shoulder Surgery 3D Planner & Positioner

      FDA OKs Shoulder Surgery 3D Planner & Positioner

      Intuitive, surgeon-driven software provides 3D pre-operative planning and 3D positioners for intra-operative positioning.
      PR Newswire 12.10.19

    • Spine/Neurology
      Clinical Study of Cell Therapy for Disc Degeneration Clears Final Planned Safety Review

      Clinical Study of Cell Therapy for Disc Degeneration Clears Final Planned Safety Review

      Patient enrollment in this U.S. study will now continue through completion of 60 total subjects.
      PR Newswire 12.10.19

    • Spine/Neurology
      InVivo Therapeutics Attains 25 Percent Enrollment in Spinal Cord Injury Study

      InVivo Therapeutics Attains 25 Percent Enrollment in Spinal Cord Injury Study

      Fourteen sites currently are open for patient enrollment.
      Business Wire 12.09.19


    • BioPrax Biofilm Disruption Device Granted FDA Breakthrough Device Designation

      BioPrax Biofilm Disruption Device Granted FDA Breakthrough Device Designation

      Product is designed to help eliminate biofilm infections on prosthetic knee implants during early intervention procedures.
      PR Newswire 12.09.19

    • Spine/Neurology
      Orthofix Appoints New Spine Business Leader

      Orthofix Appoints New Spine Business Leader

      Kevin Kenny was previously VP of U.S. sales for Spine and Biologics at Medtronic.
      Business Wire 12.05.19

    • Packaging & Sterilization
      Viant to Halt EtO Sterilization at Michigan Plant by End of Year

      Viant to Halt EtO Sterilization at Michigan Plant by End of Year

      EGLE had been investigating over the past year and issued Viant several violations for inadequate capture and control of ethylene oxide emissions.
      Michigan Department of Environment, Great Lakes, and Energy (EGLE) 12.04.19

    • Spine/Neurology
      Synaptive Medical

      Synaptive Medical's Modus V Expands Into Spine Market

      Modus V’s robotic arm moves automatically based on the positions of tracked surgical instruments.
      Business Wire 12.04.19

    • 3-D Printing/Additive Mfg. | Biologics | Materials
      3D-Printed Graftless Bone Transplants Go to Clinical Trials

      3D-Printed Graftless Bone Transplants Go to Clinical Trials

      ADAM is piloting the use of ceramics and polymer in 3D-printed bone implants, able to be produced at commodity prices.
      PR Newswire 12.04.19

    • Extremities
      CrossRoads Extremity Systems Acquires Implant Systems from Surgical Frontiers

      CrossRoads Extremity Systems Acquires Implant Systems from Surgical Frontiers

      The add-on acquisition furthers CrossRoads' strategy to build a market-leading company in the high-growth orthopedic extremities sector.
      PR Newswire 12.04.19


    Breaking News
    • FDA OKs First Test to Help Screen for Newborn Duchenne Muscular Dystrophy
    • Europe, North America Comprise More Than 80 Percent of Global Bone Marrow Transplantation Demand
    • TriMed Closes Out FDA Warning Letter
    • FDA OKs Shoulder Innovations' Augmented Glenoids for Total Shoulder System
    • OrthoGrid Systems Receives FDA 510(k) Clearance for New PhantomMSK Trauma Application
    View Breaking News >
    CURRENT ISSUE

    November/December 2019

    • From Nitinol to Nanotubes: A Materials Science Roundtable
    • In Good Repair: Trauma Technologies Under Review
    • Anxious Undertones: A Review of 2019
    • View More >
    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Deerland Obtains Certification from Australia’s Therapeutic Goods Administration
    OptiMSM Shown to Improve Hair & Nail Appearance and Condition
    DCC Acquires Contract Manufacturer Ion Laboratories
    Coatings World

    Latest Breaking News From Coatings World

    Arkema: Bostik Acquires Danish Company LIP
    Axalta Adds New Epoxy Primer to Tufcote Liquid Industrial Coatings Portfolio
    Chromaflo Technologies Promotes Sergio Duenas to Country Manager of Mexico
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    FDA OKs World's First Single-Use Duodenoscope
    Dr. Stephen Hahn Confirmed as New FDA Leader
    FDA OKs First Test to Help Screen for Newborn Duchenne Muscular Dystrophy
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Sanofi Awarded $226M by US Gov't for Pandemic Influenza Preparedness
    Amgen Selects Location For R&D Facility
    Arctoris Opens Oxford R&D Facility
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Time Features 5 Best Beauty Inventions
    CES 2020 Preview - Innovation Award Honorees in Health & Wellness
    Prada & L’Oréal Sign Long-Term Licensing Deal
    Happi

    Latest Breaking News From Happi

    Cosmetic Assessments Revealed at CIR Panel
    T-Boz Launches CBD Line
    DRF and Flowerkist Develop CBD Range
    Ink World

    Latest Breaking News From Ink World

    Ripon Printers Adds Ricoh Pro C9210
    LogoJet Opens Bogota, Colombia Office
    Canon Solutions America Powers University of Notre Dame Athletics' Printing Capabilities
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    GSE products provide quality assurance for Pharmalabel
    Luminer promotes Heather Bookman to prepress manager
    Materials Exchange launches to solve excess inventory issue
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    DuPont to Acquire Osmosis Specialist
    Nice-Pak to Expand in Indiana
    Hospeco Launches Compact Fem Hy Dispenser
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    FDA OKs First Test to Help Screen for Newborn Duchenne Muscular Dystrophy
    Europe, North America Comprise More Than 80 Percent of Global Bone Marrow Transplantation Demand
    TriMed Closes Out FDA Warning Letter
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    3D Printing Materials Market to Grow at 23.9% CAGR Through 2025: GVR
    Kyocera, TactoTek Collaborate on Injection Molded Structural Electronics Solutions
    Toray Opens R&D Innovation Center for the Future

    Copyright © 2019 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.